Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 7/20 | 0.46 |
| ▸ | USP2 | O75604 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3960313 | 0.86 | CYP2D6 (0.46) | CYP2D6USP2CYP2C9CYP1A2CYP3A4 | |
| SCHEMBL4129353 | 0.86 | PKM (0.48) | USP2 | |
| SCHEMBL10177234 | 0.81 | — | — | |
| SCHEMBL5317700 | 0.78 | CYP2D6 (0.42) | CYP2D6USP2CYP2C9CYP1A2CYP3A4 | |
| SCHEMBL6358085 | 0.78 | CYP2D6 (0.42) | CYP2D6USP2CYP2C9CYP1A2CYP3A4 | |
| SCHEMBL1969086 | 0.77 | CYP4F2 (0.55) | CYP3A4CYP2C19MEN1KMT2AALDH1A1 | |
| SCHEMBL4542407 | 0.77 | PKM (0.42) | USP2 | |
| SCHEMBL3293624 | 0.76 | CYP4F2 (0.53) | CYP3A4CYP2C19MEN1KMT2ATSHR | |
| SCHEMBL6731550 | 0.73 | CYP3A4 (0.39) | CYP2C9CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL28877805 | 0.73 | USP2 (0.47) | CYP2D6USP2CYP2C9CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013197-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | AstraZeneca AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007102771-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2007-09-13 | — | — | WO | disclosed |
| WO-2005117882-A9 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS | INCYTE CORP (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2005117882-A9 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS | INCYTE CORP (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2005117882-A2 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS | INCYTE CORPORATION (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050250789-A1 | Hydroxamic acid derivatives as metalloprotease inhibitors | INCYTE CORPORATION | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250789-A1 | Hydroxamic acid derivatives as metalloprotease inhibitors | MMP9, MMP17, MMP25 | CYP2D6 1191/4885USP2 2343/4885CYP2C9 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.